SCHEMBL18293186

SCHEMBL18293186

COCCNCCC(=O)Nc1sc2c(c1-c1nc3ccccc3s1)CCN(C(C)C)C2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 10/20 0.75
USP2 O75604 2/20 0.71
KDM4E B2RXH2 2/20 0.71
NPC1 O15118 2/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
POLB P06746 1/20 0.71
HTT P42858 1/20 0.71
RECQL P46063 1/20 0.71
RAB9A P51151 1/20 0.71
BLM P54132 1/20 0.71
ATM Q13315 1/20 0.62
MYC P01106 1/20 0.58
ALDH1A1 P00352 2/20 0.58
MAPT P10636 2/20 0.58
UHRF1 Q96T88 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
LMNA P02545 3/20 0.54
TP53 P04637 1/20 0.54
RAD52 P43351 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18293245 0.91 APEX1 (0.83) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18293088 0.91 APEX1 (0.82) APEX1USP2KDM4ENPC1MEN1
SCHEMBL20248853 0.90 APEX1 (0.61) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18293321 0.90 APEX1 (0.78) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18285972 0.89 APEX1 (0.77) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18293200 0.89 APEX1 (0.81) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18293204 0.88 APEX1 (0.76) APEX1USP2KDM4ENPC1MEN1
SCHEMBL20248795 0.88 APEX1 (0.78) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18285877 0.88 APEX1 (0.80) APEX1USP2KDM4ENPC1MEN1
SCHEMBL18293190 0.88 APEX1 (0.75) APEX1USP2KDM4ENPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1196/4885USP2 4320/4885KDM4E 4565/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1879/4885USP2 4506/4885KDM4E 4623/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1879/4885USP2 4506/4885KDM4E 4623/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 APEX1 1196/4885USP2 4320/4885KDM4E 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.